Dexmedetomidine Versus Midazolam for Intensive Care Sedation of Children

Ullevaal University Hospital40 enrolled

Overview

Dexmedetomidine will be tested against midazolam in a prospective, randomized, double-blind study of intensive care children, age 2-17 years. The investigators' primary hypothesis is that time from end of medication to extubation will be shorter with dexmedetomidine sedation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE

Enrollment

Conditions

Sedation

Interventions

dexmedetomidineDRUG

Dexemedethomidine is given as major sedative drug

MidazolamDRUG

Midazolam is given as major sedative drug

Eligibility

Sex: ALLMin age: 2 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * informed consent from parents * age between 2 and 18 years * anticipated need of respirator treatment for more than 24 hrs * included in study within 48 hrs of admission to intensive care unit (ICU) Exclusion Criteria: * severe, unstable circulatory failure * severe intracranial or spinal trauma with circulatory instability * sever bradycardia or atrioventricular (A-V) block * liver failure * less than 50% chance of anticipated survival * known allergy to study drugs

Locations (1)

Dept of Anesthesiology, Oslo University Hospital, Ullevaal

Oslo, Norway

RECRUITING

Outcomes

Primary Outcomes

Time from end of sedation to extubation

Time frame: 1-24 hrs

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.